Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer

verfasst von: Lu Zheng, Wei Gong, Ping Liang, XiaoBing Huang, Nan You, Ke Qiang Han, Yu Ming Li, Jing Li

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aims to investigate effects of alpha-fetoprotein (AFP)-activated phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway on hepatocellular carcinoma cell proliferation. Active cirrhosis patients after hepatitis B infection (n = 20) and viral hepatitis patients with hepatocellular carcinoma (HCC) (n = 20) were selected as the subjects of the present study. Another 20 healthy subjects were selected as the control group. The serum AFP expression and liver tissue PI3K and Akt gene mRNA expression were detected. The hepatoma cell model HepG2 which had a stable expression of AFP gene was used. Real-time quantitative PCR and Western blot and other methods were used to analyze the intracellular PI3K and Akt protein levels. Compared with control group and cirrhosis group, the serum AFP levels in HCC group significantly increased, and the tissue PI3K and Akt mRNA expression also significantly increased. HepG2 cells were intervened using AFP, in which the PIK and Akt protein expression significantly increased. After intervention by use of AFP monoclonal antibodies or LY294002 inhibitor, the PIK and Akt protein expression in HepG2 cell was significantly decreased (P < 0.05). AFP can promote the proliferation of hepatoma cells via activation of PI3K/Akt signaling pathway.
Literatur
1.
Zurück zum Zitat Zhao Y, Wang Q, Deng X, Shi P, Wang Z. Quantitative assessment of the association between GSTP1 gene Ile105Val polymorphism and susceptibility to hepatocellular carcinoma. Tumour Biol. 2013;34:2121–6.CrossRefPubMed Zhao Y, Wang Q, Deng X, Shi P, Wang Z. Quantitative assessment of the association between GSTP1 gene Ile105Val polymorphism and susceptibility to hepatocellular carcinoma. Tumour Biol. 2013;34:2121–6.CrossRefPubMed
2.
Zurück zum Zitat Wu D, Jiang H, Gu Q, Zhang D, Li Z. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumour Biol. 2013;34:3265–9.CrossRefPubMed Wu D, Jiang H, Gu Q, Zhang D, Li Z. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumour Biol. 2013;34:3265–9.CrossRefPubMed
3.
Zurück zum Zitat Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Int Hepatol Commun. 1996;5:62–73.CrossRef Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Int Hepatol Commun. 1996;5:62–73.CrossRef
4.
Zurück zum Zitat Montalto G, Iovanna JL, Soresi M, Dusetti N, Carroccio A, Barthelemy-Bialas S, et al. Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: comparison with alpha-fetoprotein. Oncology. 1998;55:421–5.CrossRefPubMed Montalto G, Iovanna JL, Soresi M, Dusetti N, Carroccio A, Barthelemy-Bialas S, et al. Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: comparison with alpha-fetoprotein. Oncology. 1998;55:421–5.CrossRefPubMed
5.
Zurück zum Zitat McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(suppl):3–8.CrossRefPubMed McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(suppl):3–8.CrossRefPubMed
6.
Zurück zum Zitat Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. Hepatology. 2007;46:2042–4.CrossRef Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. Hepatology. 2007;46:2042–4.CrossRef
7.
Zurück zum Zitat Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 2001;226:377–408. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 2001;226:377–408.
8.
Zurück zum Zitat Si S, Sun Y, Li Z, et al. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma. Gene Ther. 2006;13:1603–10.CrossRefPubMed Si S, Sun Y, Li Z, et al. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma. Gene Ther. 2006;13:1603–10.CrossRefPubMed
9.
Zurück zum Zitat Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol. 2004;10:819–24.PubMedPubMedCentral Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol. 2004;10:819–24.PubMedPubMedCentral
10.
Zurück zum Zitat Zhang XL, Shi JQ, Zuo SH. A comparative study of the expression of ras oncogenic protein P21 and oncofetal protein AFP, CEA in human hepatocellular carcinoma (HCC). Zhonghua Bing Li Xue Za Zhi. 1994;23:155–8.PubMed Zhang XL, Shi JQ, Zuo SH. A comparative study of the expression of ras oncogenic protein P21 and oncofetal protein AFP, CEA in human hepatocellular carcinoma (HCC). Zhonghua Bing Li Xue Za Zhi. 1994;23:155–8.PubMed
11.
Zurück zum Zitat Semenkova LN, Dudich EI, Dudich IV, et al. Alpha-fetoprotein as a TNF-resistance factor for human hepato-carcinoma cell line HepG2. Tumor Biol. 1997;18:30–40.CrossRef Semenkova LN, Dudich EI, Dudich IV, et al. Alpha-fetoprotein as a TNF-resistance factor for human hepato-carcinoma cell line HepG2. Tumor Biol. 1997;18:30–40.CrossRef
12.
Zurück zum Zitat Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2013. doi:10.1007/s13277-013-1330-x Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1330-x
13.
Zurück zum Zitat Li F, Fan YC, Gao S, Sun FK, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosom Cancer. 2014;53:90–7.CrossRefPubMed Li F, Fan YC, Gao S, Sun FK, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosom Cancer. 2014;53:90–7.CrossRefPubMed
14.
Zurück zum Zitat Yau WY, Shih HC, Tsai MH, Sheu JC, Chen CH, Chow LP. Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma. J Proteomics. 2013;94C:346–58.CrossRef Yau WY, Shih HC, Tsai MH, Sheu JC, Chen CH, Chow LP. Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma. J Proteomics. 2013;94C:346–58.CrossRef
15.
Zurück zum Zitat Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, et al. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget. 2013;4:1618–31.CrossRefPubMedPubMedCentral Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, et al. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget. 2013;4:1618–31.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, Yao Z. Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell. J Drug Target. 2014;22:146–55. Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, Yao Z. Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell. J Drug Target. 2014;22:146–55.
17.
Zurück zum Zitat Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012;3:e259.CrossRefPubMedPubMedCentral Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012;3:e259.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Wang RY, Chen L, Chen HY, Hu L, Li L, Sun HY, et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology. 2013;145:1436–48.CrossRefPubMed Wang RY, Chen L, Chen HY, Hu L, Li L, Sun HY, et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology. 2013;145:1436–48.CrossRefPubMed
19.
Zurück zum Zitat Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013;380:57–66.CrossRefPubMed Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013;380:57–66.CrossRefPubMed
Metadaten
Titel
Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer
verfasst von
Lu Zheng
Wei Gong
Ping Liang
XiaoBing Huang
Nan You
Ke Qiang Han
Yu Ming Li
Jing Li
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1535-z

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.